In accordance to this hypothesis, HCT116 cells and DLD1, which bear PI3K activating mutations, are sensitized to SM83/CPT treatment when pre-treated with AKT inhibitors only in the presence of oncogenic KRAS, supporting the notion that AKT is protecting from oncogenic KRAS-dependent cancer cell sensitization (Figure 7). This evidence concerns the gene AKT1 and cancer.